Ocular Pain - Pipeline Review, H2 2016

Choose Licence

 

Ocular Pain - Pipeline Review, H2 2016 Summary Global Markets Directs, Ocular Pain - Pipeline Review, H2 2016?, provides an overview of the Ocular Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ocular Pain - The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects - The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ocular Pain Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ocular Pain Overview 7 Therapeutics Development 8 Pipeline Products for Ocular Pain - Overview 8 Ocular Pain - Therapeutics under Development by Companies 9 Ocular Pain - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Ocular Pain - Products under Development by Companies 13 Ocular Pain - Companies Involved in Therapeutics Development 14 D. Western Therapeutics Institute, Inc. 14 InSite Vision Incorporated 15 Kala Pharmaceuticals, Inc. 16 Ocular Therapeutix, Inc. 17 Reata Pharmaceuticals, Inc. 18 Sylentis S.A.U. 19 Valeant Pharmaceuticals International, Inc. 20 Ocular Pain - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 (bromfenac sodium + dexamethasone acetate) - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 bromfenac sodium - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 dexamethasone acetate SR - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Drug for Ocular Pain - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ISV-705 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ketorolac tromethamine - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 loteprednol etabonate - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 loteprednol etabonate next generation - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 NT-71 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 NT-72 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 omaveloxolone - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 RX-10045 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SYL-1001 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Ocular Pain - Dormant Projects 59 Ocular Pain - Product Development Milestones 60 Featured News & Press Releases 60 Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite 60 Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 60 Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 61 Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 61 Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 62 May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 62 Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 63 Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 63 Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64 Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64 Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 65 Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 66 Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 67 Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70

List of Tables Number of Products under Development for Ocular Pain, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 14 Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016 15 Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 16 Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016 17 Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 18 Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016 19 Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Assessment by Combination Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Ocular Pain - Dormant Projects, H2 2016 59


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports